Skip to main content
Healthcare

STAT+: In China, a flood of controversial clinical trials slows to a trickle 

STAT+: In China, a flood of controversial clinical trials slows to a trickle 

Feed excerpt — reported by STAT News

Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and U.S. investors facing an uncertain future.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.